David Donahue, DO
Psychiatry · Venice, FLNPI 1871589028
Payments from drug & device makers
Across 407 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Neurocrine Biosciences, Inc.$786
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$688
- Otsuka America Pharmaceutical, Inc.$581
- Alkermes, Inc.$479
- Johnson & Johnson$455
- plus $4K from 21 others
What the payments were for
- Food & beverage$7,854100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 85 | $1,192 |
| Neurocrine Biosciences, Inc. | 28 | $786 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 30 | $688 |
| Otsuka America Pharmaceutical, Inc. | 34 | $581 |
| Alkermes, Inc. | 23 | $479 |
| Johnson & Johnson | 18 | $455 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $427 |
| Sunovion Pharmaceuticals Inc. | 18 | $378 |
| Teva Pharmaceuticals USA, Inc. | 18 | $354 |
| Axsome Therapeutics, Inc. | 14 | $352 |
| Almatica Pharma LLC | 19 | $319 |
| Bausch Health US, LLC | 15 | $313 |
| Lundbeck LLC | 13 | $305 |
| Vanda Pharmaceuticals Inc. | 10 | $242 |
| Noven Therapeutics, LLC | 13 | $220 |
| Corium, LLC | 15 | $204 |
| Idorsia Pharmaceuticals US Inc | 9 | $173 |
| Tris Pharma Inc | 5 | $104 |
| Merck | 4 | $75 |
| Shire North American Group Inc | 3 | $66 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| Aytu Biopharma, Inc. | 2 | $27 |
| Neos Therapeutics, LP | 1 | $17 |
| Tonix Medicines, Inc. | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $15 |
How this compares
$7,863 in reported general payments places this provider in the 85th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 25 | $58,486 |
| VraylarCariprazine Hcl | 28 | $47,916 |
| TrintellixVortioxetine Hydrobromide | 18 | $14,511 |
| VyvanseLisdexamfetamine Dimesylate | 35 | $14,329 |
| Aripiprazole | 153 | $12,778 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 202 | $9,328 |
| Lisdexamfetamine Dimesylate | 41 | $8,432 |
| Bupropion XlBupropion Hcl | 330 | $7,311 |
| Methylphenidate ErMethylphenidate Hcl | 66 | $6,403 |
| Vilazodone Hcl | 46 | $6,231 |
| CymbaltaDuloxetine Hcl | 24 | $6,126 |
| Quetiapine Fumarate | 219 | $5,978 |
| Duloxetine Hcl | 241 | $5,376 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 122 | $4,480 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 160 | $4,076 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $581 | $58,48625 claims |
| AbbVieVraylar | $1,192 | $47,91628 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $427 | $28,84053 claims |
| Almatica Pharma LLCSertraline Hcl | $319 | $1,565235 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Venice
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
- Olga LapeyraLauderhill$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.